![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ALG14 |
Gene summary for ALG14 |
![]() |
Gene information | Species | Human | Gene symbol | ALG14 | Gene ID | 199857 |
Gene name | ALG14 UDP-N-acetylglucosaminyltransferase subunit | |
Gene Alias | CMS15 | |
Cytomap | 1p21.3 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q96F25 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
199857 | ALG14 | S028 | Human | Liver | HCC | 6.73e-06 | 4.08e-01 | 0.2503 |
199857 | ALG14 | S029 | Human | Liver | HCC | 5.69e-10 | 6.58e-01 | 0.2581 |
199857 | ALG14 | C04 | Human | Oral cavity | OSCC | 7.34e-14 | 6.90e-01 | 0.2633 |
199857 | ALG14 | C21 | Human | Oral cavity | OSCC | 5.93e-44 | 1.02e+00 | 0.2678 |
199857 | ALG14 | C30 | Human | Oral cavity | OSCC | 1.89e-33 | 1.19e+00 | 0.3055 |
199857 | ALG14 | C38 | Human | Oral cavity | OSCC | 4.30e-07 | 5.61e-01 | 0.172 |
199857 | ALG14 | C43 | Human | Oral cavity | OSCC | 1.71e-03 | 1.44e-01 | 0.1704 |
199857 | ALG14 | C46 | Human | Oral cavity | OSCC | 3.77e-11 | 2.70e-01 | 0.1673 |
199857 | ALG14 | C51 | Human | Oral cavity | OSCC | 5.51e-10 | 3.60e-01 | 0.2674 |
199857 | ALG14 | C57 | Human | Oral cavity | OSCC | 2.44e-07 | 2.58e-01 | 0.1679 |
199857 | ALG14 | C06 | Human | Oral cavity | OSCC | 6.37e-06 | 9.92e-01 | 0.2699 |
199857 | ALG14 | C07 | Human | Oral cavity | OSCC | 4.53e-06 | 7.77e-01 | 0.2491 |
199857 | ALG14 | C08 | Human | Oral cavity | OSCC | 3.36e-16 | 3.33e-01 | 0.1919 |
199857 | ALG14 | C09 | Human | Oral cavity | OSCC | 3.90e-08 | 2.00e-01 | 0.1431 |
199857 | ALG14 | LN22 | Human | Oral cavity | OSCC | 3.55e-07 | 5.84e-01 | 0.1733 |
199857 | ALG14 | LN46 | Human | Oral cavity | OSCC | 3.19e-08 | 2.79e-01 | 0.1666 |
199857 | ALG14 | LP15 | Human | Oral cavity | LP | 4.21e-06 | 7.38e-01 | 0.2174 |
199857 | ALG14 | LP17 | Human | Oral cavity | LP | 2.94e-04 | 6.08e-01 | 0.2349 |
199857 | ALG14 | SYSMH2 | Human | Oral cavity | OSCC | 9.33e-14 | 4.13e-01 | 0.2326 |
199857 | ALG14 | SYSMH3 | Human | Oral cavity | OSCC | 7.31e-22 | 4.40e-01 | 0.2442 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000648714 | Esophagus | ESCC | protein N-linked glycosylation | 51/8552 | 65/18723 | 6.41e-08 | 1.13e-06 | 51 |
GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
GO:00064882 | Esophagus | ESCC | dolichol-linked oligosaccharide biosynthetic process | 14/8552 | 18/18723 | 5.77e-03 | 2.14e-02 | 14 |
GO:00064902 | Esophagus | ESCC | oligosaccharide-lipid intermediate biosynthetic process | 14/8552 | 19/18723 | 1.27e-02 | 4.21e-02 | 14 |
GO:00064873 | Liver | Cirrhotic | protein N-linked glycosylation | 30/4634 | 65/18723 | 1.40e-04 | 1.36e-03 | 30 |
GO:000648711 | Liver | HCC | protein N-linked glycosylation | 48/7958 | 65/18723 | 2.85e-07 | 5.00e-06 | 48 |
GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
GO:00064875 | Oral cavity | OSCC | protein N-linked glycosylation | 44/7305 | 65/18723 | 2.63e-06 | 3.26e-05 | 44 |
GO:0006488 | Oral cavity | OSCC | dolichol-linked oligosaccharide biosynthetic process | 15/7305 | 18/18723 | 1.53e-04 | 1.07e-03 | 15 |
GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
GO:0006490 | Oral cavity | OSCC | oligosaccharide-lipid intermediate biosynthetic process | 15/7305 | 19/18723 | 4.64e-04 | 2.76e-03 | 15 |
GO:00091011 | Oral cavity | OSCC | glycoprotein biosynthetic process | 151/7305 | 317/18723 | 1.01e-03 | 5.26e-03 | 151 |
GO:00064864 | Oral cavity | OSCC | protein glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0051023 | Esophagus | ESCC | N-Glycan biosynthesis | 39/4205 | 53/8465 | 3.26e-04 | 1.15e-03 | 5.89e-04 | 39 |
hsa005136 | Esophagus | ESCC | Various types of N-glycan biosynthesis | 31/4205 | 42/8465 | 1.23e-03 | 3.78e-03 | 1.93e-03 | 31 |
hsa0051033 | Esophagus | ESCC | N-Glycan biosynthesis | 39/4205 | 53/8465 | 3.26e-04 | 1.15e-03 | 5.89e-04 | 39 |
hsa0051313 | Esophagus | ESCC | Various types of N-glycan biosynthesis | 31/4205 | 42/8465 | 1.23e-03 | 3.78e-03 | 1.93e-03 | 31 |
hsa005104 | Liver | Cirrhotic | N-Glycan biosynthesis | 32/2530 | 53/8465 | 3.82e-06 | 4.10e-05 | 2.53e-05 | 32 |
hsa005134 | Liver | Cirrhotic | Various types of N-glycan biosynthesis | 26/2530 | 42/8465 | 1.65e-05 | 1.41e-04 | 8.69e-05 | 26 |
hsa0051011 | Liver | Cirrhotic | N-Glycan biosynthesis | 32/2530 | 53/8465 | 3.82e-06 | 4.10e-05 | 2.53e-05 | 32 |
hsa0051311 | Liver | Cirrhotic | Various types of N-glycan biosynthesis | 26/2530 | 42/8465 | 1.65e-05 | 1.41e-04 | 8.69e-05 | 26 |
hsa0051021 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
hsa005132 | Liver | HCC | Various types of N-glycan biosynthesis | 30/4020 | 42/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 30 |
hsa0051031 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
hsa005133 | Liver | HCC | Various types of N-glycan biosynthesis | 30/4020 | 42/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 30 |
hsa005105 | Oral cavity | OSCC | N-Glycan biosynthesis | 39/3704 | 53/8465 | 9.77e-06 | 4.36e-05 | 2.22e-05 | 39 |
hsa005135 | Oral cavity | OSCC | Various types of N-glycan biosynthesis | 29/3704 | 42/8465 | 8.03e-04 | 2.32e-03 | 1.18e-03 | 29 |
hsa0051012 | Oral cavity | OSCC | N-Glycan biosynthesis | 39/3704 | 53/8465 | 9.77e-06 | 4.36e-05 | 2.22e-05 | 39 |
hsa0051312 | Oral cavity | OSCC | Various types of N-glycan biosynthesis | 29/3704 | 42/8465 | 8.03e-04 | 2.32e-03 | 1.18e-03 | 29 |
hsa0051022 | Oral cavity | LP | N-Glycan biosynthesis | 31/2418 | 53/8465 | 4.86e-06 | 4.14e-05 | 2.67e-05 | 31 |
hsa0051321 | Oral cavity | LP | Various types of N-glycan biosynthesis | 22/2418 | 42/8465 | 9.58e-04 | 4.49e-03 | 2.90e-03 | 22 |
hsa0051032 | Oral cavity | LP | N-Glycan biosynthesis | 31/2418 | 53/8465 | 4.86e-06 | 4.14e-05 | 2.67e-05 | 31 |
hsa0051331 | Oral cavity | LP | Various types of N-glycan biosynthesis | 22/2418 | 42/8465 | 9.58e-04 | 4.49e-03 | 2.90e-03 | 22 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ALG14 | SNV | Missense_Mutation | c.410N>C | p.Lys137Thr | p.K137T | Q96F25 | protein_coding | tolerated(0.07) | possibly_damaging(0.589) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
ALG14 | SNV | Missense_Mutation | novel | c.263N>T | p.Arg88Leu | p.R88L | Q96F25 | protein_coding | tolerated(0.1) | benign(0.289) | TCGA-S3-AA11-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | CR |
ALG14 | SNV | Missense_Mutation | novel | c.577N>A | p.Asp193Asn | p.D193N | Q96F25 | protein_coding | deleterious(0.04) | probably_damaging(0.967) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ALG14 | SNV | Missense_Mutation | c.87N>A | p.Met29Ile | p.M29I | Q96F25 | protein_coding | tolerated(0.4) | benign(0) | TCGA-A6-6138-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ALG14 | SNV | Missense_Mutation | rs767036165 | c.641G>A | p.Arg214Gln | p.R214Q | Q96F25 | protein_coding | tolerated(0.06) | possibly_damaging(0.687) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ALG14 | SNV | Missense_Mutation | rs767402341 | c.248N>A | p.Ser83Tyr | p.S83Y | Q96F25 | protein_coding | tolerated(0.07) | benign(0.091) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
ALG14 | SNV | Missense_Mutation | rs767402341 | c.248C>A | p.Ser83Tyr | p.S83Y | Q96F25 | protein_coding | tolerated(0.07) | benign(0.091) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALG14 | SNV | Missense_Mutation | c.166C>T | p.Leu56Phe | p.L56F | Q96F25 | protein_coding | tolerated(0.06) | possibly_damaging(0.877) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ALG14 | SNV | Missense_Mutation | novel | c.562N>A | p.Leu188Met | p.L188M | Q96F25 | protein_coding | deleterious(0.03) | probably_damaging(0.934) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALG14 | SNV | Missense_Mutation | c.506T>C | p.Ile169Thr | p.I169T | Q96F25 | protein_coding | deleterious(0) | possibly_damaging(0.522) | TCGA-AP-A0LD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |